Editas Medicine
Bernadette Connaughton joined the Editas Medicine Board of Directors in October 2021. Bernadette is an accomplished pharmaceutical executive with more than 30 years of global strategic, commercial, and biopharmaceutical industry expertise.
Bernadette spent her career at Bristol-Myers Squibb, building a consistent track record of achieving sales growth, improving operational models, and increasing profitability in the U.S., European, and Asian markets. She most recently served as President of Intercontinental. In this role, she developed suCcessful, multi-year commercialization strategies for several oncology, virology, and immunology products.
Bernadette currently serves on the Board of Directors of Syneos Health, InC., Zealand Pharma A/S, and Halozyme Therapeutics, Inc. She also serves on the Board of Trustees of the Boys and Girls Club of Mercer County, New Jersey. She was previously a member of the Board of Directors of Visterra, Inc.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Editas Medicine
5 followers
Editas Medicine is a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Their goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.